I've just taken a quick tour of some NASDAQ investor forum websites (the first couple of pages as they come up on Google) Summit presence is indeed very low. Most seem to carry out of date info about the company ... very little buzz that I can see about "Diff Gone" (can't ever see myself using the proper ridiculous name ... on the webcast this week even Glyn got it wrong!)
THE GOOD NEWS THIS WEEK MEANS WE FINALLY HAVE SO MUCH TO PLAY FOR ... if I thought it would do any good, I'd take it on myself to join a NASDAQ forum a day ... and plant a few seeds of info. (Which begs the question - is there anything our USA Summit contingent could be doing that doesn't involve a P.R. spend?) GLA
Did email Richard Pye about any significance or hidden meaning in the letters that make up “ Ridinilazole” ?
ood fun trying to guess true value of our assets - C-Diff treatment cure Ridinilazole asset price just went up !
Still early days though on market /scientific reaction to our fantastic primary c-diff results although as others have mentioned monies invested in SUMM/SMMT now greatly de-risked ! Expect to see investor awareness communication more vocal going forward !
C-Diff ,geographic spread , number of patients treated per site, plus full breakdown of detailed results still to come from the Secondary Outcome Measures:
e.g. Number of treatments related to C. difficile isolates of different antimicrobial resistance phenotypes across different ribotypes etc - so wider the data patient range captured the better Ridinilazole results will look !
Secondary Outcome measures ! •Plasma and faecal concentrations of SMT19969 [ Time Frame: 40 Days ] [ Designated as safety issue: No ] Using laboratory analysis
•To assess the safety and tolerability of SMT19969 compared with vancomycin [ Time Frame: 40 days ] [ Designated as safety issue: Yes ]
Assessment of the Adverse Events (AEs) and Serious Adverse Events (SAEs) reported within the study
Other Outcome Measures: •To assess the qualitative and quantitative effect of SMT19969 and Vancomycin on the bowel flora of subjects [ Time Frame: 40 days ] [ Designated as safety issue: No ]
Using microbiology, sequencing, metagenomic and bioinformatics techniques."
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.